Key result
Lercanidipine demonstrated good antihypertensive effects, organoprotection, metabolic neutrality, and safety in mild to moderate hypertension.
Why the study?
Does lercanidipine improve blood pressure control and reduce complications in patients with mild to moderate arterial hypertension?
Does lercanidipine improve blood pressure control and reduce complications in patients with mild to moderate arterial hypertension?
Lercanidipine is an effective and safe third-generation calcium channel blocker for managing mild to moderate hypertension and slowing the progression of its complications.
Answers are grounded in this paper and cite their sources.
May support lercanidipine in mild-moderate hypertension; leaves open prospective confirmation of organoprotection.
Despite progress in reducing the risk of hypertension (HT) complications, control of blood pressure (BP) levels remains inadequate. Dihydropyridine calcium channel blockers show antihypertensive effect due to significant vasoselective action with a minimal impact on a conductive system of the heart. Lercanidipine is a dihydropyridine calcium channel blocker of the third generation with high lipophilicity and long-lasting action. Lercanidipine had shown both in monotherapy and in combination with ACE inhibitors or angiotensin II blockers the good antihypertensive effect with stable BP profile throughout the day, organoprotection that slowed down the progression of HT complications, metabolic neutrality and safety in mild to moderate HT.
No takes yet. Share an insight, caveat, or question.
E. EL. Trisvetova (2015) conducted a review in Arterial hypertension. Lercanidipine was evaluated. Lercanidipine demonstrated good antihypertensive effects, organoprotection, metabolic neutrality, and safety in mild to moderate hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: